All News

Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis

Cancer taught me not to worry about the little things.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

I transformed my mindset to maximize healing before, during and after prostate cancer treatment.

Drink this between meals to help gain or maintain a healthy weight during and after cancer treatment.

Treatments with JAK inhibitors are continuing to make their way into the MPN space, providing symptom relief, but not yet a cure.

Artificial intelligence is becoming increasingly popular and can even write generic poems about the cancer experience. However, I feel that they cannot compare to the writings of people who actually lived with the disease.

For patients with a history of cancer or who are genetically predisposed to it — as well as the general population — unintended weight loss may be the first sign of the disease, research showed.

After seeing my friend get off the merry-go-round of advanced cancer treatment, I am starting to think more seriously and soberly about my next options and decisions.

Patients with MPNs should consult with their treating physician to individualize a healthy, nutritious diet to help ease symptoms.

Researchers may have uncovered new ways to help patients with accelerated-phase and blast-phase MPNs live longer by borrowing therapies from other blood cancers.

I recently underwent genetic testing to see if I had any mutations that could be associated with an increased cancer risk.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.

Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.

Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.

I’m mourning the death of a patient with cancer who I had never met in person, yet I loved and admired her just the same.

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.

Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.